| 2.39 -0.03 (-1.24%) | 07-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.15 | 1-year : | 3.61 |
| Resists | First : | 2.7 | Second : | 3.09 |
| Pivot price | 2.35 |
|||
| Supports | First : | 2.07 | Second : | 1.72 |
| MAs | MA(5) : | 2.46 |
MA(20) : | 2.36  |
| MA(100) : | 1.41 |
MA(250) : | 1.22 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 53.9 |
D(3) : | 63.8 |
| RSI | RSI(14): 51.6 |
|||
| 52-week | High : | 3.09 | Low : | 0.4 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CTMX ] has closed below upper band by 43.5%. Bollinger Bands are 26.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.42 - 2.44 | 2.44 - 2.45 |
| Low: | 2.32 - 2.34 | 2.34 - 2.35 |
| Close: | 2.36 - 2.39 | 2.39 - 2.41 |
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Tue, 20 May 2025
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story - simplywall.st
Tue, 20 May 2025
CytomX Therapeutics (CTMX) Maintains "Buy" Rating with $5.00 Price Target | CTMX Stock News - GuruFocus
Thu, 15 May 2025
After pivots and layoffs, CytomX Therapeutics smells success, $100 million payoff - The Business Journals
Wed, 14 May 2025
CytomX Therapeutics Stock (CTMX): Momentum from Promising Trials - Value The Markets
Tue, 13 May 2025
CytomX Therapeutics Reports Q1 2025 Results and Progress - TipRanks
Mon, 12 May 2025
CytomX Therapeutics Inc earnings beat by $0.21, revenue topped estimates - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 158 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 51 (%) |
| Shares Short | 20,790 (K) |
| Shares Short P.Month | 17,730 (K) |
| EPS | 0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.31 |
| Profit Margin | 28.1 % |
| Operating Margin | 44.4 % |
| Return on Assets (ttm) | 15.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 22.7 % |
| Gross Profit (p.s.) | 0.93 |
| Sales Per Share | 0.93 |
| EBITDA (p.s.) | 0.23 |
| Qtrly Earnings Growth | 60.5 % |
| Operating Cash Flow | -81 (M) |
| Levered Free Cash Flow | -53 (M) |
| PE Ratio | 4.97 |
| PEG Ratio | 0 |
| Price to Book value | 7.7 |
| Price to Sales | 2.55 |
| Price to Cash Flow | -4.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|